Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA x CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study

被引：0

作者：

Costa, Luciano ^{[1
]}

Bar, Noffar ^{[2
]}

Mateos, Maria-Victoria ^{[3
]}

Ribas, Paz ^{[4
]}

Hansson, Markus ^{[5
]}

Paris, Laura ^{[6
]}

Hofmeister, Craig ^{[7
]}

Rodriguez-Otero, Paula

Bermudez, Maria Aranzazu ^{[9
]}

Santoro, Armando ^{[8
,10
]}

Yee, Andrew ^{[11
]}

Creignou, Maria ^{[12
]}

Encinas, Cristina ^{[13
]}

Cerchione, Claudio ^{[14
]}

de la Rubia, Javier ^{[15
]}

Oriol, Albert ^{[16
]}

Ferstl, Barbara ^{[17
]}

Besemer, Britta ^{[18
]}

Chen, Jinjie ^{[19
]}

Boss, Isaac ^{[19
]}

Gaudy, Allison ^{[19
]}

Hsu, Kevin ^{[19
]}

Godwin, Colin ^{[19
]}

San-Miguel, Jesus ^{[20
]}

Wong, Sandy ^{[21
]}

机构：

[1] Univ Alabama Birmingham, Birmingham, AL USA

[2] Yale Univ, Sch Med, New Haven, CT USA

[3] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[4] Hosp Univ Dr Peset Aleixandre, Valencia, Spain

[5] Skane Univ Hosp, Lund, Sweden

[6] ASST Papa Giovanni XXIII, Bergamo, Italy

[7] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[8] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[9] Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain

[10] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Milan, Italy

[11] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA

[12] Karolinska Univ Hosp, Stockholm, Sweden

[13] Hosp Gen Univ Gregorio Maranon HGUGM, IiSGM, Madrid, Spain

[14] Ist Scientif Romagnolo Studio & Cura Tumori IRST, Meldola, Italy

[15] Univ Hosp La Fe, Dept Hematol, Valencia, Spain

[16] Hosp Germans Trias i Pujol, Catalan Inst Oncol & Josep Carreras Inst, Badalona, Spain

[17] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen, Germany

[18] Univ Tubingen Hosp, Tubingen, Germany

[19] Bristol Myers Squibb, Princeton, NJ USA

[20] Inst Invest Navarra, Ctr Invest Med Aplicada, Ctr Invest Biomed Red Canc, Canc Ctr Clin Univ Navarra, Pamplona, Spain

[21] Univ Calif San Francisco, San Francisco, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-033

引用

页码：S52 / S53

页数：2

共 50 条

[31] Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.
Touzeau, Cyrille
Krishnan, Amrita Y.
Moreau, Philippe
Perrot, Aurore
Usmani, Saad Zafar
Manier, Salomon
Cavo, Michele
Martinez-Chamorro, Carmen
Nooka, Ajay K.
Martin, Thomas G.
Karlin, Lionel
Leleu, Xavier
Bahlis, Nizar J.
Besemer, Britta
Pei, Lixia
Verona, Raluca
Girgis, Suzette
Uhlar, Clarissa
Kobos, Rachel
Garfall, Alfred L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[32] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
Mohty, Mohamad
Tomasson, Michael H.
Arnulf, Bertrand
Bahlis, Nizar J.
Prince, H. Miles
Niesvizky, Ruben
Rodriguez-Otero, Paula
Martinez-Lopez, Joaquin
Koehne, Guenther
Jethava, Yogesh
Gabayan, A. Eli
Stevens, Don A.
Nooka, Ajay K.
Raje, Noopur S.
Iida, Shinsuke
Leip, Eric
Conte, Umberto
Czibere, Akos Gabor
Viqueira, Andrea
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[33] A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).
Rodriguez-Otero, Paula
D'Souza, Anita
Reece, Donna Ellen
van de Donk, Niels W. C. J.
Chari, Ajai
Krishnan, Amrita Y.
Martin, Thomas G.
Mateos, Maria-Victoria
Morillo, Daniel
Hurd, David Duane
Rosinol, Laura
Balari, Anna Sureda
Wasch, Ralph
Vishwamitra, Deeksha
Lin, Shun Xin Wang
Prior, Thomas
Vandenberk, Lien
Smit, Marie-Anne Damiette
Rocafiguera, Albert Oriol
Dholaria, Bhagirathbhai R.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[34] Final Results from the First-in -Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Vogl, Dan T.
Atrash, Shebli
Holstein, Sarah A.
Nadeem, Omar
Benson, Don M.
Suryanarayan, Kaveri
Liu, Yuyin
Collins, Sabrina
Parot, Xavier
Kaufman, Jonathan L.
BLOOD, 2022, 140 : 1357 - 1359
[35] UCARTCS1A, an Allogeneic CAR T-Cell Therapy Targeting CS1 in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Translational Results from a First-in-Human Phase I Trial (MELANI-01)
Patel, Krina
Bharathan, Mini
Esteva, Francisco J.
Siegel, David
Rossi, Adriana
Frattini, Mark G.
Smith, Julianne
Brownstein, Carrie
MOLECULAR THERAPY, 2021, 29 (04) : 59 - 60
[36] Long-Term Follow-Up From the MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels W. C. J.
Moreau, Philippe
Garfall, Alfred L.
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Trancucci, Danielle
Verona, Raluca I.
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S25 - S26
[37] POPULATION PHARM ACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) x CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Polepally, A.
Badillo, J.
Rinas, M.
Ahsan, A.
Bueno, O.
Talati, C.
Menon, R.
Engelhardt, B.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S69 - S69
[38] Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Subklewe, Marion y
Stein, Anthony
Walter, Roland B.
Bhatia, Ravi
Wei, Andrew H.
Ritchie, David
Bucklein, Veit
Vachhani, Pankit
Dai, Tian
Hindoyan, Antreas
Agarwal, Suresh
Anderson, Abraham
Khaldoyanidi, Sophia
Ravandi, Farhad
BLOOD, 2019, 134
[39] First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Lonial, Sagar
van de Donk, Niels W. C. J.
Popat, Rakesh
Zonder, Jeffrey A.
Minnema, Monique C.
Larsen, Jeremy
Tuong Vi Nguyen
Chen, Min S.
Bensmaine, Amine
Cota, Mariana
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[40] Long-term follow-up from MajesTEC-1 of Teclistamab, a B-cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Donk, Van De N. W.
Moreau, P.
Garfall, A. L.
Bhutani, M.
Oriol, A.
Nooka, A. K.
Martin, T. G.
Rosinol, L.
Mateos, M. -V.
Bahlis, N.
Popat, R.
Besemer, B.
Lopez, Martinez J.
Krishnan, A.
Delforge, M.
Trancucci, D.
Verona, R., I
Stephenson, T.
Chastain, K.
Sidana, S.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 124 - 124

← 1 2 3 4 5 →